SAN DIEGO, CA — September 30, 2025 — Leads & Copy — aTyr Pharma, Inc. (Nasdaq: ATYR) presented additional findings from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis at the European Respiratory Society (ERS) Congress 2025 in Amsterdam, Netherlands.
The study showed improvements in Fatigue Assessment Scale (FAS) and King’s Sarcoidosis Questionnaire-General Health scores at week 48 in the 5.0 mg/kg efzofitimod treatment group versus placebo (p=0.0226 and p=0.0197, respectively). Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr Pharma, noted that these improvements address critical symptoms and quality of life measures for pulmonary sarcoidosis patients, and were achieved rapidly and sustained throughout the study. While the study did not meet its primary endpoint, efzofitimod has demonstrated the potential to improve multiple disease-related health outcomes.
The ERS presentation included analyses of additional pre-specified outcomes, demonstrating clinical improvements in mean change from baseline in the FAS Total Score (p=0.0226) and KSQ-General Health score (p=0.0197) in patients treated with 5.0 mg/kg efzofitimod vs placebo. Treatment with efzofitimod was also associated with a trend toward a greater proportion of patients achieving steroid-free status for at least six months. Clinical benefit for 5.0 mg/kg efzofitimod was observed across multiple study efficacy parameters at week 48 compared to placebo, including complete steroid withdrawal and KSQ-Lung score improvement (p=0.0196), improvement in KSQ-Lung score change from baseline (p=0.0479), preservation of forced vital capacity and a well-tolerated safety profile.
The study’s statistical analysis plan was designed on a hierarchical assessment basis. Since the primary endpoint was not met, all subsequent statistical testing is reported as nominal findings.
Pulmonary sarcoidosis is an inflammatory disease characterized by granulomas in one or more organs. Efzofitimod is a biologic immunomodulator in clinical development for interstitial lung disease. aTyr is translating tRNA synthetase biology into new therapies for fibrosis and inflammation.
Contact: Ashlee Dunston, Sr. Director, Investor Relations and Public Affairs, adunston@atyrpharma.com
Source: aTyr Pharma, Inc.
